Navigation Links
Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
Date:9/20/2007

- Phase III data published in the American Journal of Nephrology -

DEERFIELD, Ill., Sept. 20 /PRNewswire-FirstCall/ -- Astellas Pharma US, Inc. today announced that its Phase III data on VAPRISOL was published in the September issue of the American Journal of Nephrology. In this study, VAPRISOL showed a significant increase in serum sodium concentrations in patients with hyponatremia -- a potentially life-threatening condition that occurs when the body's sodium level falls below normal.

"This study demonstrated that VAPRISOL 40 mg/day significantly increased serum [Na+] in patients with euvolemic or hypervolemic hyponatremia," said Joseph G. Verbalis, M.D., at the Georgetown University Hospital. "VAPRISOL will likely address an important clinical need for euvolemic or hypervolemic hyponatremia in hospitalized patients."

VAPRISOL is the first in a new class of arginine vasopressin (AVP) receptor antagonists. VAPRISOL blocks both V1a and V2 vasopressin receptors, resulting in increased urine output without increased sodium loss. This effect, known as "aquaresis," increases serum sodium levels and helps to restore salt and water balance in patients with hyponatremia due to increased body water (dilutional hyponatremia).

VAPRISOL is approved by the U.S. Food and Drug Administration as a treatment for euvolemic and hypervolemic hyponatremia in hospitalized patients. VAPRISOL is not indicated for the treatment of congestive heart failure. It should only be used for the treatment of hyponatremia in patients with underlying heart failure when the expected benefit of raising serum sodium outweighs the increased risk of adverse events. The approved doses for VAPRISOL include 20 mg/day and 40 mg/day. The 80 mg/day dose used in this study is not an approved dose.

In the double-blind, multicenter study, 84 patients with serum sodium levels of 115 to <130 mEq/L were randomized to receive placebo or a 20-mg intravenous bolus of conivaptan, fo
'/>"/>

SOURCE Astellas Pharma US, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... , October 17, 2014 ... ) has announced the addition of the  ... to their offering.       (Logo: ... disease in China ... changes in consumption concept, dietary habit, way ...
(Date:10/17/2014)... , October 17, 2014 /PRNewswire/ ... and Markets ( http://www.researchandmarkets.com/research/rxznjk/micro_market ) has announced ... Monitor : North American Automated External ... offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ,The report ... 2008-2018 analyzes the market of devices ...
(Date:10/17/2014)... 17, 2014 The following is being ... The Green Park Collaborative (GPC) will ... private payers, medical device and pharmaceutical companies, as ... January 12, 2015 at its first ever workshop ... loss treatments.  Participants will discuss study designs to ...
Breaking Medicine Technology:China Interventional Cardiovascular Device Industry Report 2014-2017 2China Interventional Cardiovascular Device Industry Report 2014-2017 3Micro Market Monitor : North American Automated External Defibrillators (AED) Market 2Green Park Collaborative to Discuss Comparative Effectiveness and Value of Weight Loss Treatments 2
... April 13, 2011 ThermoGenesis Corp. (NASDAQ: ... that process and store adult stem cells, said today that ... Central Drugs Standard Control Organization of India (CDSCO), allowing its ... care system used for the preparation of cell concentrates, including ...
... 2011 Medco Health Solutions, Inc. (NYSE: MHS ... a press release before the market opens on Thursday, April ... the release, management will hold a conference call to review ... ET.   To access the live conference ...
Cached Medicine Technology:ThermoGenesis Announces Registration of Res-Q in India; Commercial Sales Expected to Begin in Current Quarter 2ThermoGenesis Announces Registration of Res-Q in India; Commercial Sales Expected to Begin in Current Quarter 3ThermoGenesis Announces Registration of Res-Q in India; Commercial Sales Expected to Begin in Current Quarter 4Medco Announces Date for Release of First-Quarter 2011 Financial Results 2
(Date:10/20/2014)... AttorneyOne.com, a recognized authority on law, update ... FDA on Sit and Slim II . , ... or use Sit and Slim II because it contains ... as weight loss product on various websites and possibly in ... 2010 for safety reasons, can significantly increase blood pressure and/or ...
(Date:10/20/2014)... Akron, OH (PRWEB) October 20, 2014 ... new Assisted Living Center on Oct. 14. The $11 ... amenities and services, and a cooked-to-order kitchen with full-service ... forward Akron’s premier choice for first class Assisted Living ... groundbreaking. “Our residents deserve the highest quality of care ...
(Date:10/20/2014)... 20, 2014 Based on a ... only imaging assays capable of determining DNA sequence, ... With these three dimensions of high-resolution data, dGH ... the widest range of disease-causing genetic rearrangements, including ... other genomic tools, including today’s advanced sequencing technologies. ...
(Date:10/20/2014)... 2014 Final Cut Pro X Plugin developers ... Citrus theme for FCPX filmmakers . , “Fun, cool, ... the Citrus theme” Says Christina Austin, CEO of Pixel Film ... professional.” , Citrus comes with all the tools needed for ... four transitions for added style, a title screen for an ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 It’s hard to ... many orphans and vulnerable children around the world, it’s a ... some people, many children are forced to walk barefoot on ... their families or play with their friends. , Buckner ... with Air1 Radio in October to encourage support ...
Breaking Medicine News(10 mins):Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Rockynol Retirement Community Expands Assisted Living Center 2Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3Health News:Today Pixel Film Studios Announced the Release of the Citrus theme for Final Cut Pro X 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 3
... NEWPORT BEACH, Calif., Feb. 7 Nationwide,Health Properties, Inc. ... will,release its fourth quarter earnings on Monday, February 25, ... Stock Exchange. The Company will host a,conference call on ... a.m. Eastern time) in order to present the Company,s ...
... Breast Cancer Movement Gathers Record Attendance for Annual ... ... Susan G. Komen for the Cure(R), the,world,s largest and most progressive ... Affiliate Leadership,Conference Feb. 7-9 at the Hilton Anatole in Dallas. The ...
... in Florida and one in Kansas, SANTA ... REIT, Inc. has acquired Medical Portfolio 1. The ... 1 consists of five medical office buildings, Doctor,s,Medical ... Brandon,Medical Plaza and Central Florida SurgiCenter. The portfolio, ...
... PICK: VEGF-B helps nerve cells cheat death without unwanted side ... family of proteins, VEGF, has recently been shown to protect ... its clinical utility in this regard is limited, because it ... In a new study, Xuri Li and colleagues at the ...
... High-Value Jobs For Commonwealth, HARRISBURG, Pa., Feb. ... better able to put promising Pennsylvania,pharmaceuticals, biotech, medical ... for growth, Governor Edward G. Rendell said, with ... sciences industry remains one of the most dynamic ...
... Memory Pharmaceuticals,Corp. (Nasdaq: MEMY ) today ... President & Chief Executive Officer. In support of ... MPM,Capital, Great Point Partners, Oxford Biosciences and Venrock, ... who has served as the,Company,s President & Chief ...
Cached Medicine News:Health News:NHP Announces Fourth Quarter Earnings Release Date and Conference Call/Webcast 2Health News:NHP Announces Fourth Quarter Earnings Release Date and Conference Call/Webcast 3Health News:Susan G. Komen for the Cure(R) Hosts Annual Affiliate Leadership Conference in Dallas 2Health News:Susan G. Komen for the Cure(R) Hosts Annual Affiliate Leadership Conference in Dallas 3Health News:Grubb & Ellis Healthcare REIT Acquires Medical Portfolio 1 2Health News:Grubb & Ellis Healthcare REIT Acquires Medical Portfolio 1 3Health News:Grubb & Ellis Healthcare REIT Acquires Medical Portfolio 1 4Health News:JCI online early table of contents: Feb. 7, 2008 2Health News:JCI online early table of contents: Feb. 7, 2008 3Health News:JCI online early table of contents: Feb. 7, 2008 4Health News:JCI online early table of contents: Feb. 7, 2008 5Health News:JCI online early table of contents: Feb. 7, 2008 6Health News:JCI online early table of contents: Feb. 7, 2008 7Health News:JCI online early table of contents: Feb. 7, 2008 8Health News:Pennsylvania Gov. Rendell: $10 Million Partnership With Harrisburg Venture Capital Firm Boosts PA's Life Sciences Industry 2Health News:Memory Pharmaceuticals Appoints Vaughn M. Kailian Interim President & Chief Executive Officer 2Health News:Memory Pharmaceuticals Appoints Vaughn M. Kailian Interim President & Chief Executive Officer 3Health News:Memory Pharmaceuticals Appoints Vaughn M. Kailian Interim President & Chief Executive Officer 4
... wide Mini-Sub cell GT system for ... acids in agarose gels includes a ... electrodes, a 15 x 7 cm ... two casting gates, and two 1.5 ...
... your data for future generations. Most gels can ... backing plate of our gel dryer, covering them ... over them to hold the cellophane flat. Tut's ... with an open area somewhat larger than the ...
... data for future generations. Most gels can be ... plate of our gel dryer, covering them with ... them to hold the cellophane flat. Tut's Tombs ... an open area somewhat larger than the gel ...
... Breeze Air Gel Dryer : Dry up to ... gels 8 10 cm without a vacuum ... drying, or no heat for controlled drying of ... dried gels. Add and remove gels at any ...
Medicine Products: